CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.